Epstein-Barr Virus Infections: all 164 studies
Page 1 of 2. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.
- Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young AdultsNot yet recruitingNCT07888088Phase 1
- 25BT056: Basket Study of Viral Cytotoxic T LymphocytesNot yet recruitingNCT07873970Early Phase 1
- Epstein-Barr Virus Antibodies in Egyptian Patients With Multiple SclerosisNot yet recruitingNCT07846943
- Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative DiseasesRecruitingNCT07727083
- Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.RecruitingNCT07685457Not applicable
- BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCLRecruitingNCT07678229Phase 3
- Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.RecruitingNCT07670468Phase 1/2
- Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemiaNot yet recruitingNCT07614282Phase 1
- mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young AdultsNot yet recruitingNCT07557602Phase 1
- A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of AgeRecruitingNCT07478952Phase 1
- Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT07368634Phase 1/2
- Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive DonorsRecruitingNCT07368153Phase 2
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT07358910
- Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot StudyRecruitingNCT07294547Not applicable
- Zuberitamab for EBV Infection Post-Allo-HSCTNot yet recruitingNCT07261215Phase 2
- EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07138989Phase 2
- Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.Not yet recruitingNCT07133776Phase 1/2
- TETRAVI Expanded Access ProgramAvailableNCT07104591
- Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host DiseaseRecruitingNCT07029958Phase 4
- R-MVST Cells for Treatment of Viral Infections in Children and Young AdultsRecruitingNCT06926894Phase 1
- Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised ImmunityRecruitingNCT06909110Phase 1/2
- Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV InfectionRecruitingNCT06908096Phase 1
- Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk AreasRecruitingNCT06870435Not applicable
- A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)RecruitingNCT06789159Phase 1
- Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory LymphomaNot yet recruitingNCT06788600
- "Xijiang Project" Screening Cohort for NPCRecruitingNCT06787456
- Investigating Epstein-Barr Virus Associated ConjunctivitisEnrolling by invitationNCT06689397
- Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal CarcinomaRecruitingNCT06682442Not applicable
- A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCTNot yet recruitingNCT06491719Not applicable
- Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam TherapyNot yet recruitingNCT06480903
- Graves' Disease Induced by Epstein-Barr Virus Lytic ReactivationNot yet recruitingNCT06426758
- Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal CarcinomaRecruitingNCT06321939
- Epstein-Barr Virus and Cancer RisksRecruitingNCT06203314
- Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV InfectionRecruitingNCT06135922Phase 1
- Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal InvolvementNot yet recruitingNCT06131489
- Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCTRecruitingNCT06119256Phase 1
- Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCTNot yet recruitingNCT06075927Phase 1/2
- Anti-viral T-cell Therapy by Gamma CaptureEnrolling by invitationNCT06027879Phase 1/2
- Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaNot yet recruitingNCT05970627Phase 2
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsRecruitingNCT05592626Phase 1/2
- Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma ScreeningRecruitingNCT05447169
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 1
- R-MVST Cells for Treatment of Viral InfectionsRecruitingNCT05183490Phase 1
- Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV InfectionRecruitingNCT05127980
- Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney AllograftRecruitingNCT04989491Phase 4
- Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV InfectionsRecruitingNCT04832607Phase 3
- EBV Specific T-Lymphocytes for Treatment of EBV-Positive LymphomaRecruitingNCT04664179Phase 1
- Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus InfectionRecruitingNCT04308278Phase 4
- TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.RecruitingNCT04013802Phase 1
- Surveillance and Tracking the Outcomes of Chronic Latent EBV InfectionRecruitingNCT03491605
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyRecruitingNCT03394365Phase 3
- EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV InfectionRecruitingNCT03266653Phase 2
- Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingNCT03258567Phase 2
- Third Party Viral Specific T-cells (VSTs)RecruitingNCT02532452Phase 2
- Comparative Autoantibody and Immunologic Cell Marker StudyEnrolling by invitationNCT02422875
- Donor-Derived Viral Specific T-cells (VSTs)RecruitingNCT02048332Phase 1/2
- Genetic Studies of Chronic Active Epstein-Barr DiseaseRecruitingNCT00032513
- Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell TransplantTerminatedNCT05305040Phase 2/3Results posted
- An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory LymphomasTerminatedNCT05011058Phase 2Results posted
- Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell TransplantCompletedNCT04693637Phase 2/3Results posted
- Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy AdultsCompletedNCT04645147Phase 1Results posted
- Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBVTerminatedNCT04364178Phase 1/2Results posted
- Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)TerminatedNCT03769467Phase 1/2Results posted
- Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)TerminatedNCT03682055Phase 1/2Results posted
- Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesCompletedNCT03397706Phase 1/2Results posted
- Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)CompletedNCT01998633Phase 2Results posted
- ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney TransplantationCompletedNCT01972035Phase 2Results posted
- Chemotherapy for Relapsed Epstein Barr Virus Associated LymphomaTerminatedNCT01964755Phase 2Results posted
- Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
- Bortezomib Plus Rituximab for EBV+ PTLDCompletedNCT01058239Phase 2Results posted
- A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal CarcinomaCompletedNCT00834093Phase 2Results posted
- Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus InfectionCompletedNCT00575185Phase 1/2Results posted
- A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 YearsActive, not recruitingNCT07536048
- Environmental Risk Factors in Multiple Sclerosis Development: Epidemiological Study of EBV Infection and Vitamin D Deficiency in RIS PatientsCompletedNCT07256431
- A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell LymphomaSuspendedNCT06761677Phase 1/2
- Evaluation of CMV/EBV-CMI in Haploid HSCTStatus unknownNCT06554197
- Effect of Epstein-Barr Virus on Macrophage M2/M1 Migration and EphA2 Expression in Adverse Drug ReactionsActive, not recruitingNCT06456086
- A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT06256484Phase 1
- Study on Infectious Mononucleosis in MunichCompletedNCT06002802
- Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH PatientsStatus unknownNCT05841342
- A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy ParticipantsActive, not recruitingNCT05831111Phase 1
- Epstein Barr Virus Infection in Patients With Radiologically Isolated SyndromeCompletedNCT05815108
- L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLHCompletedNCT05775705Not applicable
- Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative PersonsCompletedNCT05683834Phase 1/2
- A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.Status unknownNCT05682703
- Relationship of EBV-positive Gastric Cancer and Multiple Genes Associated With Gastric CarcinogenesisCompletedNCT05604378
- Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric CancerCompletedNCT05535569Phase 1/2
- Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCTStatus unknownNCT05532826Not applicable
- Rituximab Monotherapy for EBV-HLH and CAEBVStatus unknownNCT05384743Phase 3
- A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and AdultsActive, not recruitingNCT05164094Phase 1/2
- Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line TherapyStatus unknownNCT05039580Phase 4
- Verification of Harmonization of Plasma Epstein-Barr Virus DNA MeasurementsStatus unknownNCT05037357
- Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive LymphomasWithdrawnNCT04952584Phase 1
- Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative StudiesActive, not recruitingNCT04925544Phase 2
- Study on the Application of Saliva EBV-DNA Detection in EBV Infection Related DiseasesStatus unknownNCT04782674
- PD-1 Antibody for Reactive EBV After BMTStatus unknownNCT04690036Early Phase 1
- A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated DiseasesActive, not recruitingNCT04554914Phase 2
- Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot TrialStatus unknownNCT04507477Phase 1/2
- Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal CancerWithdrawnNCT04231864Phase 2
- EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant RecipientsCompletedNCT04189835